MarketCap
Facebook
X
Telegram
Heron Therapeutics Cash and Cash Equivalents | HRTX
Annual Cash and Cash Equivalents Heron Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.6 M | 25.8 M | 28.7 M | 15.4 M | 90.5 M | 105 M | 71.9 M | 31.8 M | 145 M | 13.4 M | 75.2 M | 72.7 M | 72.3 M | 53.5 M | 18 M | 2.11 M | 7.59 M | 9.97 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 145 M | 2.11 M | 48.2 M |
Quarterly Cash and Cash Equivalents Heron Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.8 M | 26.1 M | 15.4 M | 43.1 M | 16.5 M | 19.3 M | 90.5 M | 25.7 M | 18.4 M | 20.4 M | 90.5 M | 34.9 M | 13.5 M | 27.1 M | 15.4 M | 50.4 M | 48.6 M | 56.9 M | 90.5 M | 160 M | 191 M | 59.7 M | 105 M | 105 M | 105 M | 105 M | 71.9 M | 71.9 M | 71.9 M | 71.9 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 145 M | 145 M | 145 M | 145 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 75.2 M | 75.2 M | 75.2 M | 75.2 M | 72.7 M | 72.7 M | 72.7 M | 72.7 M | 72.3 M | 72.3 M | 72.3 M | 72.3 M | 53.5 M | 53.5 M | 53.5 M | 53.5 M | 18 M | 18 M | 18 M | 18 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 191 M | 13.4 M | 60.9 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
8.78 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
1.91 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Synthetic Biologics
SYN
|
13.1 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
95.9 M | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
2.14 B | - | - | $ 866 M |  China |
 |
Corner Growth Acquisition Corp.
COOL
|
21.6 K | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Qilian International Holding Group Limited
QLI
|
9.82 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
10.3 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
CureVac N.V.
CVAC
|
482 M | - | - | $ 867 M |  Germany |
 |
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
54 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
89 M | - | - | $ 4.9 B |  Britain |
|
Galera Therapeutics
GRTX
|
6.38 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
1.83 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
46.9 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M | Germany |
 |
Codexis
CDXS
|
50.8 M | $ 1.46 | 2.82 % | $ 127 M | USA |
 |
Ardelyx
ARDX
|
68 M | $ 3.78 | 1.89 % | $ 911 M | USA |
 |
Affimed N.V.
AFMD
|
38.5 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 23.9 | 1.01 % | $ 3.04 B | USA |
 |
Assembly Biosciences
ASMB
|
58.4 M | $ 36.6 | 1.3 % | $ 410 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
1.87 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
12.4 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
5.88 M | $ 7.12 | 6.91 % | $ 4.76 M | USA |
 |
Generation Bio Co.
GBIO
|
76.3 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3.5 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
1.45 B | - | - | $ 3.37 B | China |
 |
Axsome Therapeutics
AXSM
|
323 M | $ 206.68 | 0.16 % | $ 10.3 B | USA |
 |
GlycoMimetics
GLYC
|
213 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
238 M | $ 56.8 | 0.94 % | $ 1.63 B | USA |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
254 M | - | 1083.1 % | $ 745 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.31 B | $ 66.53 | 0.15 % | $ 12.8 B | USA |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Bicycle Therapeutics plc
BCYC
|
628 M | $ 4.3 | 1.42 % | $ 298 M | Britain |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
ChromaDex Corporation
CDXC
|
64.8 M | - | -0.88 % | $ 598 M | USA |